HUP0105301A2 - Riluzol és alfa-tokoferol kombinációját tartalmazó gyógyszerkészítmény és alkalmazása - Google Patents

Riluzol és alfa-tokoferol kombinációját tartalmazó gyógyszerkészítmény és alkalmazása

Info

Publication number
HUP0105301A2
HUP0105301A2 HU0105301A HUP0105301A HUP0105301A2 HU P0105301 A2 HUP0105301 A2 HU P0105301A2 HU 0105301 A HU0105301 A HU 0105301A HU P0105301 A HUP0105301 A HU P0105301A HU P0105301 A2 HUP0105301 A2 HU P0105301A2
Authority
HU
Hungary
Prior art keywords
alpha
pharmaceutical composition
composition containing
combination
riluzole
Prior art date
Application number
HU0105301A
Other languages
English (en)
Inventor
Michel Dib
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of HUP0105301A2 publication Critical patent/HUP0105301A2/hu
Publication of HUP0105301A3 publication Critical patent/HUP0105301A3/hu
Publication of HU226067B1 publication Critical patent/HU226067B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • External Artificial Organs (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

A találmány tárgyát a-tokoferol és riluzol vagy ez utóbbi egygyógyszerészetileg elfogadható sójának, 10 és 400 tömegrész közöttimennyiségű riluzolból, és 250 és 4000 tömegrész közötti mennyiségű a-tokoferolból álló, adott esetben kompatibilis és gyógyszerészetilegelfogadható hígítószert vagy adjuvánst is tartalmazó kombinációjáttartalmazó gyógyszerkészítmény, és annak az izomsorvadásos szklerózislaterális kezelésére való alkalmazása képezi. Ó
HU0105301A 1998-11-13 1999-11-09 Pharmaceutical composition containing riluzole and alpha-tocopherol combination and its use HU226067B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9814250A FR2785808B1 (fr) 1998-11-13 1998-11-13 Association riluzole et alpha-tocopherol
PCT/FR1999/002753 WO2000028992A1 (fr) 1998-11-13 1999-11-09 Association riluzole et alpha-tocopherol

Publications (3)

Publication Number Publication Date
HUP0105301A2 true HUP0105301A2 (hu) 2002-05-29
HUP0105301A3 HUP0105301A3 (en) 2006-07-28
HU226067B1 HU226067B1 (en) 2008-04-28

Family

ID=9532674

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0105301A HU226067B1 (en) 1998-11-13 1999-11-09 Pharmaceutical composition containing riluzole and alpha-tocopherol combination and its use

Country Status (23)

Country Link
US (2) US6642262B2 (hu)
EP (1) EP1128829B1 (hu)
JP (1) JP4693241B2 (hu)
KR (1) KR100641472B1 (hu)
CN (1) CN1177587C (hu)
AT (1) ATE295168T1 (hu)
AU (1) AU776242B2 (hu)
BR (1) BR9915292A (hu)
CA (1) CA2350671C (hu)
CZ (1) CZ298808B6 (hu)
DE (1) DE69925301T2 (hu)
DK (1) DK1128829T3 (hu)
EA (1) EA003671B1 (hu)
ES (1) ES2239858T3 (hu)
FR (1) FR2785808B1 (hu)
HK (1) HK1041220B (hu)
HU (1) HU226067B1 (hu)
IL (1) IL142708A0 (hu)
NO (1) NO328349B1 (hu)
PT (1) PT1128829E (hu)
TR (1) TR200101346T2 (hu)
WO (1) WO2000028992A1 (hu)
ZA (1) ZA200103810B (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786101B1 (fr) * 1998-11-24 2002-07-05 Aventis Laboratoire Utilisation de la nicergoline dans le traitement de la spasticite
US20090149518A1 (en) * 2005-10-18 2009-06-11 Ono Pharmaceutical Co., Ltd. Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis
US20070099156A1 (en) * 2005-10-28 2007-05-03 Jeff Wagner Self-etching dental primer compositions and methods and systems utilizing such compositions
FR2957077B1 (fr) * 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
WO2014145776A2 (en) * 2013-03-15 2014-09-18 Baylor College Of Medicine Msp and its receptors in the therapy of amyotrophic lateral sclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
US5843641A (en) * 1993-02-26 1998-12-01 Massachusetts Institute Of Technology Methods for the daignosis, of familial amyotrophic lateral sclerosis
US6380252B1 (en) * 1996-07-05 2002-04-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1
US5780489A (en) * 1996-08-21 1998-07-14 Brooks; Benjamin Rix Method for treating amyotrophic lateral sclerosis
JP3889844B2 (ja) * 1997-02-10 2007-03-07 龍兒 梶 筋萎縮性側索硬化症治療剤
FR2782008B1 (fr) * 1998-08-07 2003-04-25 Sod Conseils Rech Applic Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique

Also Published As

Publication number Publication date
CN1326348A (zh) 2001-12-12
BR9915292A (pt) 2001-08-07
NO20012308L (no) 2001-05-10
DE69925301D1 (de) 2005-06-16
CA2350671A1 (fr) 2000-05-25
DE69925301T2 (de) 2006-01-26
HK1041220B (zh) 2005-07-22
US20030125363A1 (en) 2003-07-03
KR20010080407A (ko) 2001-08-22
EP1128829B1 (fr) 2005-05-11
JP4693241B2 (ja) 2011-06-01
US20020019426A1 (en) 2002-02-14
ZA200103810B (en) 2002-08-12
EP1128829A1 (fr) 2001-09-05
NO328349B1 (no) 2010-02-01
TR200101346T2 (tr) 2002-05-21
AU776242B2 (en) 2004-09-02
US6642262B2 (en) 2003-11-04
ES2239858T3 (es) 2005-10-01
FR2785808B1 (fr) 2002-12-06
WO2000028992A1 (fr) 2000-05-25
ATE295168T1 (de) 2005-05-15
CN1177587C (zh) 2004-12-01
JP2002529506A (ja) 2002-09-10
CZ20011561A3 (cs) 2001-08-15
FR2785808A1 (fr) 2000-05-19
KR100641472B1 (ko) 2006-10-31
NO20012308D0 (no) 2001-05-10
IL142708A0 (en) 2002-03-10
CZ298808B6 (cs) 2008-02-06
HUP0105301A3 (en) 2006-07-28
HU226067B1 (en) 2008-04-28
EA200100530A1 (ru) 2001-10-22
HK1041220A1 (en) 2002-07-05
CA2350671C (fr) 2010-05-04
AU1165500A (en) 2000-06-05
DK1128829T3 (da) 2005-08-29
PT1128829E (pt) 2005-07-29
EA003671B1 (ru) 2003-08-28

Similar Documents

Publication Publication Date Title
AU6613896A (en) Chemical compounds
AU6865298A (en) The use of cryoprotective agent compounds during cryosurgery
AU688952B2 (en) Thrombin inhibitors
AU3951699A (en) The use of an anti-microbial compound for disinfection
MX9704377A (es) Uso de pramipexole como agente neuroprotector.
UA34466C2 (uk) Засіб для несистемної боротьби з паразитуючими комахами
ES2114487B1 (es) Mezcla estabilizante sinergistica.
NO307336B1 (no) 2-[(Dihydro)pyrazolyl-3'-oksylmetylen]anilider, anvendelse derav, samt middel inneholdende forbindelsen og mellomprodukter for fremstilling av forbindelsen
AU4292096A (en) Use of guanylate cyclase inhibitors for reducing intraocular pressure
DE60112974D1 (en) Carbolinderivate
MX9205432A (es) Compuestos inhibidores de la biosintesis de leucotrienos y composicion farmaceutica que los contiene.
YU41199A (sh) Hinoksalindioni
DE60216233D1 (en) Carbolinderivate
AU2002213421A1 (en) Condensed pyridoindole derivatives
CA2154572A1 (fr) Application du riluzole dans le traitement du neuro-sida
MXPA02012076A (es) Compuestos quimicos.
MXPA02012659A (es) Derivados de pirazindiona condensados.
GB9514518D0 (en) Guanidine salt inhibitors of NO synthase and cyclooxygenase
AU2002213419A1 (en) Condensed pyridoindole derivatives
HUP0105301A2 (hu) Riluzol és alfa-tokoferol kombinációját tartalmazó gyógyszerkészítmény és alkalmazása
FR2718013B1 (fr) Dispositif d'enclouage centro-médullaire notamment pour fractures sous cervicales du fémur.
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
MXPA02012472A (es) Compuestos quimicos.
AU6206698A (en) Isoflavone derivatives, processes for the preparation thereof and pharmac euticalcompositions containing them
AU5622599A (en) Use of 5-amino-pyrazol-derivatives for combating micro-organisms

Legal Events

Date Code Title Description
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): DR. LANG TIVADARNE, S.B.G. & K. SZABADALMI UEGYVIVOEI IRODA, HU

Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

FH92 Termination of representative

Representative=s name: DR. LANG TIVADARNE, S.B.G. & K. SZABADALMI UEG, HU

MM4A Lapse of definitive patent protection due to non-payment of fees